Brian Taylor Slingsby - Feb 9, 2023 Form 3 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Signature
Brian Taylor Slingsby by: /s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Feb 9, 2023
Transactions value $
$0
Form type
3
Date filed
2/9/2023, 06:53 PM
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MLYS Common Stock 4.63M Feb 9, 2023 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MLYS Series A Preferred Stock Feb 9, 2023 Common Stock 2.17M See footnote F1, F2
holding MLYS Series B Preferred Stock Feb 9, 2023 Common Stock 2.14M See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F2 Each share of preferred stock of the Issuer is convertible into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) at any time. The preferred stock will automatically convert into common stock upon closing of the Issuer's public offering.

Remarks:

EXHIBIT LIST: EX-24 Brian Taylor Slingsby POA